(June 17, 2008) Arizona-based SenesTech, Inc., announces a partnership with Australia on technology to reduce rodent population and increase food supply. SenesTech, Inc. is developing a technology that will target the fertility of rice field rats in Southeast Asia. If successful, the chemical spaying procedure could prevent uncontrolled populations of rodents that often eat and contaminate rice harvests. It is estimated that rodents are capable of destroying up to one-third of the rice crop each year. More...

(June 6, 2008) The government of Luxembourg sought out TGen and two Seattle-based groups as part of an ambitious biotech push that aims to advance the European nation's scientific research, improve health care and diversify its economy. This is the first major deal secured by the Valley-based Partnership for Personalized Medicine. The personalized-medicine initiative is headed by a Nobel Prize winner, Dr. Leland Hartwell, and includes scientists from the Translational Genomics Research Institute (TGen) and the Biodesign Institute at Arizona State University. More...

(June 2, 2008) Apthera's NeuVax™ produces delays in recurrent in high-risk HER2-positive prostate cancer patients. Dr. Alton C. Morgan, President and CEO of Apthera, will present at the BIO Business Forum (6/19/08) and discuss the NeuVax results in breast cancer and prostate cancer and future development plans for the product. Apthera, Inc. is developing a pipeline of peptide-based immunotherapies for cancers that express HER2/neu, a well-validates and established oncology target. More...